Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer – A nationwide study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer – A nationwide study. / Froeding, Ligita Paskeviciute; Høgdall, Claus; Kristensen, Elisabeth; Zobbe, Vibeke; Niemann, Isa; Ørtoft, Gitte; Thranov, Ingrid; Mathiesen, Ole; Mortensen, Jann; Schnack, Tine Henrichsen.
In: Gynecologic Oncology, Vol. 156, No. 1, 2020, p. 124-130.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer – A nationwide study
AU - Froeding, Ligita Paskeviciute
AU - Høgdall, Claus
AU - Kristensen, Elisabeth
AU - Zobbe, Vibeke
AU - Niemann, Isa
AU - Ørtoft, Gitte
AU - Thranov, Ingrid
AU - Mathiesen, Ole
AU - Mortensen, Jann
AU - Schnack, Tine Henrichsen
PY - 2020
Y1 - 2020
N2 - Objective: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients. Methods: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included. Results: The SN-procedure was performed in 286 patients, of these 190 (66.4%) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1%) had one or more recurrences during a median follow-up of 30 months (range 1–83). Four patients (2.1%) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4%) experienced a local recurrence in vulva, 1 patient (0.5%) had a recurrence in the vulva and the groin and 4 patients (2.1%) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84% and 93%, respectively. The 3-year OS for patients with recurrent disease was 58%. Conclusions: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.
AB - Objective: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients. Methods: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included. Results: The SN-procedure was performed in 286 patients, of these 190 (66.4%) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1%) had one or more recurrences during a median follow-up of 30 months (range 1–83). Four patients (2.1%) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4%) experienced a local recurrence in vulva, 1 patient (0.5%) had a recurrence in the vulva and the groin and 4 patients (2.1%) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84% and 93%, respectively. The 3-year OS for patients with recurrent disease was 58%. Conclusions: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.
KW - Isolated groin recurrence
KW - Sentinel Node procedure
KW - Survival
KW - Vulva cancer
U2 - 10.1016/j.ygyno.2019.10.024
DO - 10.1016/j.ygyno.2019.10.024
M3 - Journal article
C2 - 31711658
AN - SCOPUS:85075444589
VL - 156
SP - 124
EP - 130
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -
ID: 254462690